June 2nd 2024
Pembrolizumab plus sacituzumab govitecan numerically improved PFS vs the ADC alone in HR-positive, HER2-negative metastatic breast cancer.
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
View More
Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma
View More
Go To PER in Chicago
May 31, 2024 - June 2, 2024
Register Now!
The Top 10 Oncogenic Drivers in NSCLC for 2023: What You Need to Know on Tumor Testing, Targets, and Treatment Strategies to Move the Field Forward
View More
Patient, Provider, and Caregiver Connection™: Individualizing Care for Patients with Schizophrenia—Understanding Patient Challenges and the Role of Innovative Treatment
View More
Improving Outcomes in Autoimmune Hemolytic Anemias at the Intersection Between Hematology and Oncology Care
View More
Oncology Consultations®: Next Generation SERDs—Key Data and Practical Takeaways for the Community Physician
View More
Live “Hot Seat”: Experts Face Your Hot-Button Questions on Maximizing PARP Inhibitors in Patients With CRPC
View More
Medical Crossfire®: Leveraging Multidisciplinary Teams in Early–Stage Breast Cancer When the Goal is Cure
View More
Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Expanding the Armamentarium of Actionable Mutations in NSCLC: Uncovering the Potential of CEACAM5 as a Therapeutic Target
View More
Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!
View More
The 14th Asia-Pacific Primary Liver Cancer Expert Meeting
July 18 - 20, 2024
Register Now!
23rd Annual International Congress on the Future of Breast Cancer® East
July 19-20, 2024
Register Now!
Advances In™: Targeting PSMA to Advance Diagnosis And Management Of Patients With Prostate Cancer
View More
Community Practice Connections™: 14th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies
View More
Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer
View More
Community Practice Connections™: 8th Annual School of Gastrointestinal Oncology®
View More
Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer
View More
Show Me the Data™: Do We Have Sea Change for Novel Approaches in HR+/HER2- Breast Cancer? CDK, PI3K/AKT, ADC, and Next-Gen SERD Strategies Assessed
View More
Community Practice Connections™: Controversies and Conversations About HER2- Expressing Breast Cancer…Advances in Management of HER2-Low to -Positive Disease
View More
B-Cell Tumor Board: Rendering Real World Personalized Treatment Plans in CLL/SLL and MCL Through the Lens of Emerging BTKi Evidence
View More
Cancer Summaries and Commentaries™: Clinical Updates from Chicago in Breast Cancer
View More
8th Annual School of Nursing Oncology™
August 10, 2024
Register Now!
7th Annual Live Medical Crossfire®: Hematologic Malignancies
View More
Cancer Summaries and Commentaries™: Clinical Updates in RCC from Chicago
View More
Community Practice Connections™: Integrating BTK Inhibitors Into the CLL/SLL and MCL Treatment Paradigm
View More
Community Practice Connections™: What the Community Needs to Know to Apply RLT in PSMA-Positive mCRPC in Context with Current Treatment Paradigms
View More
Community Practice Connections™: 7th Annual International Congress on Oncology Pathology
View More
Pathology Implications for CEACAM5 as a Therapeutic Target in Advanced NSCLC
View More
Pembrolizumab Plus BSC Improves OS in Advanced HCC Previously Treated With Sorafenib
The addition of pembrolizumab to best supportive care resulted in a statistically significant improvement in overall survival vs BSC alone in Asian patients with advanced hepatocellular carcinoma who previously received treatment with sorafenib, meeting the primary end point of the phase 3 KEYNOTE-394 trial.
FDA Approval Sought for Frontline Nivolumab Plus Ipilimumab or Chemo in Advanced ESCC
The FDA has accepted the supplemental biologics license applications for nivolumab plus ipilimumab and nivolumab plus fluoropyrimidine- and platinum-containing chemotherapy in the frontline treatment of adult patients with unresectable advanced, recurrent, or metastatic esophageal squamous cell carcinoma.
Janjigian Spotlights Significance of Nivolumab/Chemo Approval for Frontline Gastric Cancer
Yelena Y. Janjigian, MD, further discusses the clinical significance of the FDA approval of nivolumab plus chemotherapy in the frontline treatment of patients with gastric cancer.
FDA Grants Priority Review to Relatlimab/Nivolumab for Unresectable or Metastatic Melanoma
The FDA has granted priority review to a biologics license application for the fixed-dose combination of relatlimab plus nivolumab for the treatment of adult and pediatric patients aged 12 years and older and weighing at least 40 kg who have unresectable or metastatic melanoma.
Pembrolizumab/Chemo Nears EU Approval for Select TNBC With PD-L1 CPS ≥10
The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion of pembrolizumab plus chemotherapy in the treatment of patients with locally recurrent unresectable or metastatic triple-negative breast cancer whose tumors have a PD-L1 combined positive score of 10 or higher and who have not previously received chemotherapy for metastatic disease.
The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of nivolumab plus fluoropyrimidine and platinum-containing chemotherapy as frontline treatment for adult patients with HER2-negative advanced or metastatic gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma with a PD-L1 combined positive score of 5 or higher.
Nivolumab and Tumor-Infiltrating Lymphocyte Regimen Elicits Activity in Metastatic NSCLC
August 27th 2021Nivolumab followed by tumor-infiltrating lymphocyte therapy and maintenance nivolumab demonstrated a suitable safety profile and antitumor activity in patients with metastatic non–small cell lung cancer.
Managing Immune-Related AEs in Oncology Needs Nurse Intervention
August 19th 2021It’s imperative to stay diligent of the immune-related adverse events that patients with cancer may experience from checkpoint inhibitors and other immunotherapy agents, especially with regards to treatment continuation and keeping hospitalizations low.
FDA Approves Dostarlimab-gxly for dMMR Recurrent or Advanced Solid Tumors
The FDA has granted an accelerated approval to dostarlimab-gxly for the treatment of adult patients with mismatch repair-deficient recurrent or advanced solid tumors, as determined by an FDA-approved test, who have progressed on or following previous treatment and who have no satisfactory alternative options.
EMA Validates Applications for Nivolumab/Ipilimumab, Nivolumab/Chemo in Frontline ESCC
The European Medicines Agency has validated its Type II Variation Marketing Authorization Applications for nivolumab plus ipilimumab and nivolumab plus fluoropyrimidine- and platinum-containing chemotherapy as frontline options for adult patients with unresectable advanced, recurrent, or metastatic esophageal squamous cell carcinoma.
Non–CAR T-Based Strategies Shake Up the Management of Non-Hodgkin Lymphoma
August 13th 2021Stephen M. Ansell, MD, PhD, discusses recent progress made with non–CAR T-based approaches in the non-Hodgkin lymphoma treatment paradigm, opportunities for sequencing available options, and ongoing efforts that are picking up momentum.
ACCC Report: Immunotherapy Research Grew in 2020 Despite COVID-19 Pandemic
The COVID-19 pandemic had a relatively limited effect on immuno-oncology research, according to results from the Association of Community Cancer Centers fourth annual analysis of the IO landscape.
Cardio-oncology Specialists Pave Optimal Treatment Path for Patients With Cancer
The subspecialty of cardio-oncology has grown in recent years as improved cancer survival rates have expanded the population of long-term survivors with heightened risk of cardiovascular disease and drawn more attention to the need for preventive strategies and disease management.
Adjuvant Nivolumab Approved in Europe for Select Esophageal or GEJ Cancers
The European Commission has approved nivolumab for use as an adjuvant treatment in adult patients with esophageal or gastroesophageal junction cancer who have residual pathologic disease after neoadjuvant chemoradiation.
Pembrolizumab Plus Chemo Significantly Improves OS in Metastatic TNBC With PD-L1 CPS ≥10
The addition of pembrolizumab to chemotherapy resulted in a statistically significant and clinically meaningful improvement in overall survival vs chemotherapy alone in patients with metastatic triple-negative breast cancer whose tumors had a PD-L1 expression of a combined positive score of 10 or higher, meeting the primary end point of the phase 3 KEYNOTE-355 trial.
Roche Withdraws Application for Atezolizumab in Early or Locally Advanced TNBC in Europe
Roche Registration GmbH has withdrawn its application to extend the use of atezolizumab to the treatment of patients with early or locally advanced triple-negative breast cancer in Europe.
FDA Issues a Complete Response Letter for Retifanlimab for Squamous Cell Carcinoma of the Anal Canal
The FDA has issued a complete response letter to Incyte Corporation stating that it cannot approve the biologics license application for retifanlimab for use in adult patients with locally advanced or metastatic squamous cell carcinoma of the anal canal who have progressed on, or who are intolerant of, platinum-based chemotherapy, in its present form.
FDA Grants Regular Approval to Pembrolizumab Plus Lenvatinib for Advanced Endometrial Carcinoma
The FDA has granted a regular approval to pembrolizumab plus lenvatinib for the treatment of patients with advanced endometrial carcinoma that is not microsatellite instability high or mismatch repair deficient, who have disease progression after previous systemic therapy in any setting, and who are not candidates for curative surgery or radiation.
Nivolumab plus ipilimumab did not significantly improve overall survival over the EXTREME regimen in the frontline treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck, missing the primary end points of the phase 3 CheckMate-651 trial.
Neoadjuvant Pembrolizumab Combo Significantly Improves EFS in High-Risk Early-Stage TNBC
Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant single-agent pembrolizumab was found to significantly improve event-free survival over neoadjuvant chemotherapy followed by adjuvant placebo in patients with high-risk, early-stage triple-negative breast cancer.
Atezolizumab/Bevacizumab Demonstrates Durable Efficacy in Advanced Malignant Peritoneal Mesothelioma
The combination of atezolizumab plus bevacizumab elicited encouraging, durable responses in patients with advanced malignant peritoneal mesothelioma, irrespective of tumor mutational burden and PD-L1 expression status.
Frontline Bempegaldesleukin/Nivolumab Continues to Elicit Durable Responses in Metastatic Melanoma
The combination of bempegaldesleukin plus nivolumab continued to produce promising antitumor activity with favorable tolerability when used in the frontline treatment of patients with metastatic melanoma, according to findings from a phase 2 cohort of the phase 1/2 PIVOT-2 trial.